15-01-2018 | 13:28

The company unreasonably increased the price for the oncological agent under patent protection for nearly 35% to 159,000 RUB per package


In April 2017, FAS opened a case upon signs of “Novartis Pharma” Ltd. breaching Clause 1 Part 1 Article 10 of the Federal Law “On Protection of Competition”.


In the course of the investigation the company was requested to justify the growth of the price for “Tyverb” (“Lapatinib” International Non-Proprietary Name) from 118,000 to 159,000 RUB per package. The drug is used to treat malignant tumours.


Having considered a case, the FAS Commission concluded that the respondent, which has the dominant position on the market of medicinal drug with “Lapatinib” International Non-Proprietary Name in the Russian Federation, had fixed monopolistically high price for the drug. The FAS Commission issued an injunction to eliminate the violations.


Head of FAS Anti-Cartel Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev, said: ““Tyverb” (“Lapatinib” International Non-Proprietary Name) is not on the List of vital and essential drugs, which means that the government does not regulate the prices for it. In this context, the case opened upon a petition filed by the Moscow Government that is the Tyverb” buyer to provide treatment to patients under the government guarantees programme is a precedent. Hopefully, the pharmaceutical community will take the FAS decision into account and refuse to manipulate prices for the drugs, particularly, not included in the List of vital and essential drugs”.

Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide